Medicare could save $73B by matching drug prices of other countries, study says

Alia Paavola - Print  | 

By using external reference pricing to match U.S. drug prices to those in Japan, the U.K. or Canada,  Medicare could have saved nearly $73 billion in 2018, according to a new study published in Health Affairs.

Five things to know:

1. For the study, researchers analyzed 79 medicines that Medicare Part D spent the most on that did not have competition from lower-cost generic alternatives. All of the drugs analyzed had been on the market for at least three years.

2. For 79 brand-name prescription drugs, the U.S. price was 3.2 percent to 4.1 percent higher on average than in the other three countries.

3. If Medicare Part D adopted the average price from the other three countries, the government program could have saved $72.9 billion on sole-sourced drugs in 2018.

4. The Trump administration has proposed using an international pricing index to set prices for Medicare Part B, which covers drugs administered in a healthcare setting. The study shows the method could also reap significant savings for Medicare Part D. According to researchers, 29 other countries use reference pricing to set and negotiate drug prices.

5. "Medicare could use external reference pricing in Part D to improve affordability for patients," the study authors concluded.

Access the full study here.

More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody's says

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.